MDxHealth SA (MDXH)
USD 1.56
(6.12%)
USD 1.56
(6.12%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 18.88 Million USD | -22.25% |
| 2022 | 24.29 Million USD | 156.56% |
| 2021 | -42.94 Million USD | -52268.29% |
| 2020 | -82 Thousand USD | 99.26% |
| 2019 | -11.04 Million USD | 56.97% |
| 2018 | -25.67 Million USD | -61.06% |
| 2017 | -15.94 Million USD | 46.8% |
| 2016 | -29.96 Million USD | -1.0% |
| 2015 | -29.67 Million USD | -57.02% |
| 2014 | -18.89 Million USD | 23.44% |
| 2013 | -24.68 Million USD | -75.56% |
| 2012 | -14.05 Million USD | 1.05% |
| 2011 | -14.2 Million USD | -0.9% |
| 2010 | -14.08 Million USD | 45.49% |
| 2009 | -25.83 Million USD | 39.35% |
| 2008 | -42.59 Million USD | 11.73% |
| 2007 | -48.25 Million USD | -11.47% |
| 2006 | -43.29 Million USD | -288.54% |
| 2005 | -11.14 Million USD | -3870.94% |
| 2004 | -280.6 Thousand USD | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 26.6 Million USD | 40.88% |
| 2024 Q2 | 35.31 Million USD | 32.75% |
| 2023 Q3 | 8.01 Million USD | 617.82% |
| 2023 Q1 | -8.67 Million USD | -135.7% |
| 2023 Q2 | 1.11 Million USD | 112.88% |
| 2023 FY | 18.88 Million USD | -22.25% |
| 2023 Q4 | 18.88 Million USD | 135.53% |
| 2022 Q4 | 24.29 Million USD | 121.91% |
| 2022 Q2 | -25.65 Million USD | -138.02% |
| 2022 Q3 | 10.94 Million USD | 142.67% |
| 2022 FY | 24.29 Million USD | 156.56% |
| 2022 Q1 | 67.46 Million USD | 257.12% |
| 2021 Q2 | -16.18 Million USD | -181.34% |
| 2021 Q4 | -42.94 Million USD | -300.0% |
| 2021 FY | -42.94 Million USD | -52268.29% |
| 2021 Q1 | 19.89 Million USD | 24360.97% |
| 2021 Q3 | -10.73 Million USD | 33.65% |
| 2020 FY | -82 Thousand USD | 99.26% |
| 2020 Q1 | -13.56 Million USD | -22.76% |
| 2020 Q2 | -12.94 Million USD | 4.53% |
| 2020 Q3 | -839 Thousand USD | 93.52% |
| 2020 Q4 | -82 Thousand USD | 90.23% |
| 2019 Q1 | -11.03 Million USD | 57.01% |
| 2019 FY | -11.04 Million USD | 56.97% |
| 2019 Q2 | -10.32 Million USD | 6.42% |
| 2019 Q4 | -11.04 Million USD | 5.56% |
| 2019 Q3 | -11.69 Million USD | -13.25% |
| 2018 Q2 | -40.24 Million USD | 0.0% |
| 2018 Q3 | -25.79 Million USD | 35.9% |
| 2018 Q4 | -25.67 Million USD | 0.45% |
| 2018 FY | -25.67 Million USD | -61.06% |
| 2018 Q1 | -40.24 Million USD | -152.42% |
| 2017 Q4 | -15.94 Million USD | 1.06% |
| 2017 Q3 | -16.11 Million USD | 46.23% |
| 2017 Q2 | -29.96 Million USD | 0.0% |
| 2017 Q1 | -29.96 Million USD | -0.0% |
| 2017 FY | -15.94 Million USD | 46.8% |
| 2016 Q3 | -30.33 Million USD | -55.95% |
| 2016 Q1 | -19.45 Million USD | 34.45% |
| 2016 Q4 | -29.96 Million USD | 1.2% |
| 2016 FY | -29.96 Million USD | -1.0% |
| 2016 Q2 | -19.45 Million USD | 0.0% |
| 2015 Q1 | -40.14 Million USD | -112.42% |
| 2015 Q3 | -30.83 Million USD | 23.19% |
| 2015 FY | -29.67 Million USD | -57.02% |
| 2015 Q4 | -29.67 Million USD | 3.76% |
| 2015 Q2 | -40.14 Million USD | 0.0% |
| 2014 Q3 | -18.89 Million USD | -48.69% |
| 2014 Q2 | -12.7 Million USD | 0.0% |
| 2014 Q1 | -12.7 Million USD | 48.51% |
| 2014 Q4 | -18.89 Million USD | 0.0% |
| 2014 FY | -18.89 Million USD | 23.44% |
| 2013 FY | -24.68 Million USD | -75.56% |
| 2013 Q4 | -24.68 Million USD | 0.0% |
| 2013 Q3 | -24.68 Million USD | 23.12% |
| 2013 Q2 | -32.1 Million USD | -1.54% |
| 2013 Q1 | -31.61 Million USD | -124.89% |
| 2012 Q1 | -3.51 Million USD | 75.26% |
| 2012 FY | -14.05 Million USD | 1.05% |
| 2012 Q4 | -14.05 Million USD | 6.87% |
| 2012 Q3 | -15.09 Million USD | -83.29% |
| 2012 Q2 | -8.23 Million USD | -134.33% |
| 2011 Q4 | -14.2 Million USD | -300.0% |
| 2011 Q2 | -21.2 Million USD | -496.81% |
| 2011 FY | -14.2 Million USD | -0.9% |
| 2011 Q1 | -3.55 Million USD | 74.78% |
| 2011 Q3 | -3.55 Million USD | 83.24% |
| 2010 Q3 | -3.52 Million USD | 79.99% |
| 2010 Q1 | -3.52 Million USD | 86.37% |
| 2010 Q2 | -17.59 Million USD | -399.65% |
| 2010 FY | -14.08 Million USD | 45.49% |
| 2010 Q4 | -14.08 Million USD | -300.0% |
| 2009 Q3 | -6.45 Million USD | 0.0% |
| 2009 Q4 | -25.83 Million USD | -300.0% |
| 2009 FY | -25.83 Million USD | 39.35% |
| 2009 Q1 | -6.45 Million USD | 39.35% |
| 2009 Q2 | -6.45 Million USD | 0.0% |
| 2008 Q4 | -10.64 Million USD | 0.0% |
| 2008 Q1 | -10.64 Million USD | 11.73% |
| 2008 Q3 | -10.64 Million USD | 0.0% |
| 2008 Q2 | -10.64 Million USD | 0.0% |
| 2008 FY | -42.59 Million USD | 11.73% |
| 2007 Q4 | -12.06 Million USD | 0.0% |
| 2007 Q2 | -12.06 Million USD | 0.0% |
| 2007 Q3 | -12.06 Million USD | 0.0% |
| 2007 FY | -48.25 Million USD | -11.47% |
| 2007 Q1 | -12.06 Million USD | -11.47% |
| 2006 Q2 | -10.82 Million USD | 0.0% |
| 2006 Q3 | -10.82 Million USD | 0.0% |
| 2006 Q1 | -10.82 Million USD | -288.54% |
| 2006 FY | -43.29 Million USD | -288.54% |
| 2006 Q4 | -10.82 Million USD | 0.0% |
| 2005 FY | -11.14 Million USD | -3870.94% |
| 2005 Q2 | -2.78 Million USD | 0.0% |
| 2005 Q4 | -2.78 Million USD | 0.0% |
| 2005 Q3 | -2.78 Million USD | 0.0% |
| 2005 Q1 | -2.78 Million USD | -3870.95% |
| 2004 Q1 | -70.15 Thousand USD | 0.0% |
| 2004 FY | -280.6 Thousand USD | 0.0% |
| 2004 Q3 | -70.15 Thousand USD | 0.0% |
| 2004 Q4 | -70.15 Thousand USD | 0.0% |
| 2004 Q2 | -70.15 Thousand USD | 0.0% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| Aclaris Therapeutics, Inc. | -39.45 Million USD | 147.868% |
| Applied DNA Sciences, Inc. | -5.91 Million USD | 419.325% |
| Aspira Women's Health Inc. | -331 Thousand USD | 5805.438% |
| Biodesix, Inc. | 34.3 Million USD | 44.953% |
| BioNexus Gene Lab Corp. | -5.79 Million USD | 425.831% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 1619.392% |
| bioAffinity Technologies, Inc. | -1.24 Million USD | 1619.392% |
| Bionano Genomics, Inc. | 34.88 Million USD | 45.86% |
| CareDx, Inc | -47.97 Million USD | 139.363% |
| Check-Cap Ltd. | -24.75 Million USD | 176.285% |
| Castle Biosciences, Inc. | -83.53 Million USD | 122.608% |
| DarioHealth Corp. | -7.54 Million USD | 350.199% |
| Exact Sciences Corporation | 1.94 Billion USD | 99.031% |
| Fulgent Genetics, Inc. | -82.56 Million USD | 122.873% |
| Guardant Health, Inc. | 220.22 Million USD | 91.425% |
| ICON Public Limited Company | 3.56 Billion USD | 99.47% |
| IDEXX Laboratories, Inc. | 493.94 Million USD | 96.177% |
| Illumina, Inc. | 1.21 Billion USD | 98.444% |
| Intelligent Bio Solutions Inc. | -5.43 Million USD | 447.62% |
| iSpecimen Inc. | -2.14 Million USD | 979.427% |
| Standard BioTools Inc. | 46.5 Million USD | 59.392% |
| 23andMe Holding Co. | -141.37 Million USD | 113.358% |
| Medpace Holdings, Inc. | -103.32 Million USD | 118.277% |
| Myriad Genetics, Inc. | 88.1 Million USD | 78.564% |
| Mainz Biomed B.V. | 349.85 Thousand USD | -5297.951% |
| ENDRA Life Sciences Inc. | -2.43 Million USD | 874.133% |
| NeoGenomics, Inc. | 269.19 Million USD | 92.985% |
| Neogen Corporation | 735.62 Million USD | 97.433% |
| Inotiv, Inc. | 382.14 Million USD | 95.058% |
| Natera, Inc. | -200.1 Million USD | 109.438% |
| OpGen, Inc. | 11.89 Million USD | -58.806% |
| OPKO Health, Inc. | 230.68 Million USD | 91.813% |
| Psychemedics Corporation | 334 Thousand USD | -5554.192% |
| Prenetics Global Limited | -43.33 Million USD | 143.577% |
| Prenetics Global Limited | -43.33 Million USD | 143.577% |
| Precipio, Inc. | -386 Thousand USD | 4992.487% |
| Personalis, Inc. | -8.02 Million USD | 335.415% |
| RadNet, Inc. | 1.14 Billion USD | 98.356% |
| Sera Prognostics, Inc. | -2.02 Million USD | 1033.976% |
| Sotera Health Company | 2.02 Billion USD | 99.068% |
| Neuronetics, Inc. | 2.79 Million USD | -575.188% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 223.134% |
| Star Equity Holdings, Inc. | -15.33 Million USD | 223.134% |
| Trinity Biotech plc | 63.73 Million USD | 70.37% |
| T2 Biosystems, Inc. | 33.8 Million USD | 44.142% |
| Twist Bioscience Corporation | -192.4 Million USD | 109.815% |
| Exagen Inc. | -12.77 Million USD | 247.863% |